載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.5803
+US$0.0361 · +6.63%
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
前收盤價
US$0.5803
+US$0.0361 · +6.63%
盤中時間採用ET。市場資料可能有所延遲。
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
日內區間
目前US$0.5803
52週區間
目前US$0.5803
盤中時間採用ET。市場資料可能有所延遲。
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
日內區間
目前US$0.5803
52週區間
目前US$0.5803
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 843.6萬 USD | 846.8萬 USD | 868.7萬 USD | 871.3萬 USD | 402.5萬 USD |
| 毛利 | −843.6萬 USD | −846.8萬 USD | −868.7萬 USD | −871.3萬 USD | −402.5萬 USD |
| 研究與開發 | 6860.7萬 USD | 8674.2萬 USD | 9803.8萬 USD | 9453.7萬 USD | 5439.3萬 USD |
| 銷售、一般及管理費用 | 2472.4萬 USD | 2073.8萬 USD | 2446.8萬 USD | 2237.1萬 USD | 1438.8萬 USD |
| 營業費用 | 8489.5萬 USD | 1.07億 USD | 1.23億 USD | 1.17億 USD | 6878.1萬 USD |
| 利息收入 | 268.2萬 USD | 473.7萬 USD | 705.6萬 USD | 195.4萬 USD | 10.8萬 USD |
| 折舊和攤銷 | 843.6萬 USD | 846.8萬 USD | 868.7萬 USD | 646.7萬 USD | 296.1萬 USD |
| 營業利益 | −9333.1萬 USD | −1.16億 USD | −1.31億 USD | −1.26億 USD | −7280.6萬 USD |
| 淨利 | −9059.7萬 USD | −1.11億 USD | −1.24億 USD | −1.24億 USD | −7272.1萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$2.33
上漲空間 301.52%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI353.27萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF121.64萬0.00%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB89.01萬0.01%108.2億 USD0.44%US$206.49+3.00%
Invesco RAFI US 1500 Small-Mid ETFPRFZ17.24萬0.01%26.7億 USD0.36%US$53.16+0.64%
Invesco NASDAQ Future Gen 200 ETFQQQS10.12萬0.44%2275.83萬 USD0.20%US$42.145+1.39%
Invesco Nasdaq Biotechnology ETFIBBQ9226.770.01%1.12億 USD0.19%US$34.62+2.96%
ProShares Ultra Nasdaq BiotechnologyBIB4998.70.01%9320.36萬 USD1.19%US$110.98+5.68%
Avantis Total Equity Markets ETF 1AVTM1998.85—7.94億 USD0.23%US$55.6085+0.56%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBInvesco RAFI US 1500 Small-Mid ETFPRFZInvesco NASDAQ Future Gen 200 ETFQQQSInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAvantis Total Equity Markets ETF 1AVTMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
